- Panniculitis and vitiligo-like lesions predict a better disease response and longer time to progression in patients with advanced melanoma receiving dabrafenib-trametinib combination therapy.
Why this matters
- Immune-related skin lesions (IRSLs) may represent a useful surrogate marker for treatment response.
- Combination treatment with BRAF/MEK inhibitors is standard of care in metastatic or locally advanced BRAF V600 mutated malignant melanoma.
- 23% of patients developed IRSLs (15% panniculitis, 8% vitiligo).
- IRSL diagnosis was associated with higher disease response rates (83% vs 25%; P=.001).
- IRSLs were associated with response in multivariate analysis (HR, 0.16; P=.034).
- IRSL diagnosis was associated with longer median PFS (not reached vs 9 months; P=.001) and OS (not reached vs 13 months; P=.002).
- IRSLs were associated with longer PFS in multivariate analysis (HR, 0.19; P=.043).
- Multivariate analysis for OS was not performed.
- 52 patients with BRAF V600-mutated melanoma treated with combined dabrafenib and trametinib were analyzed for outcomes.
- Funding: Patients and families; Fondazione Internazionale di Ricerca in Medicina.
- Retrospective study.
- Small patient sample size.